Thursday, March 25, 2021 7:00:08 PM
Novavax Stock Plunges On Report That Covid Vaccine Is Facing Delays In Europe
https://www.investors.com/news/technology/nvax-stock-tumbles-raw-materials-challenges-trip-covid-vaccine/
Novavax (NVAX) is reportedly struggling to access the raw materials it needs to produce its Covid vaccine, according to a report that sent NVAX stock stumbling Thursday.
Supply talks in Europe have stalled, according to Reuters. Earlier this year, the European Union signed a deal for at least 100 million doses of the Novavax vaccine, with an option to buy another 100 million.
The vaccine isn't yet authorized anywhere. But Novavax says it has begun rolling reviews in the U.K., Europe, Canada, Australia and New Zealand. It's also in talks with the U.S. Food and Drug Administration through an open
Novavax's Covid vaccine has proved highly effective in clinical testing. Test results show it's 96.4% effective against symptomatic cases of Covid-19 caused by the original strain. That's helped boost NVAX stock this year.
That puts Novavax's drug among the top performers. Pfizer (PFE) and BioNTech (BNTX) say their drug was 95% effective in Phase 3 testing. Moderna's (MRNA) vaccine was 94.1% effective.
But, if authorized, the vaccine would be Novavax's first commercial product. A Novavax spokeswoman told Reuters the company is working "through some pandemic-related raw-materials supply shortage," but didn't give further details.
..
https://www.investors.com/news/technology/nvax-stock-tumbles-raw-materials-challenges-trip-covid-vaccine/
Novavax (NVAX) is reportedly struggling to access the raw materials it needs to produce its Covid vaccine, according to a report that sent NVAX stock stumbling Thursday.
Supply talks in Europe have stalled, according to Reuters. Earlier this year, the European Union signed a deal for at least 100 million doses of the Novavax vaccine, with an option to buy another 100 million.
The vaccine isn't yet authorized anywhere. But Novavax says it has begun rolling reviews in the U.K., Europe, Canada, Australia and New Zealand. It's also in talks with the U.S. Food and Drug Administration through an open
Novavax's Covid vaccine has proved highly effective in clinical testing. Test results show it's 96.4% effective against symptomatic cases of Covid-19 caused by the original strain. That's helped boost NVAX stock this year.
That puts Novavax's drug among the top performers. Pfizer (PFE) and BioNTech (BNTX) say their drug was 95% effective in Phase 3 testing. Moderna's (MRNA) vaccine was 94.1% effective.
But, if authorized, the vaccine would be Novavax's first commercial product. A Novavax spokeswoman told Reuters the company is working "through some pandemic-related raw-materials supply shortage," but didn't give further details.
My post is for Your Eyes only and my entertainment
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
